Prescription Drug Pricing
Expert articles and analysis related to prescription drug pricing.
AI Summary — Last 30 Days
In the past 30 days, the Trump administration’s CMS has finalized significant updates to Medicare Advantage and Part D payment models, including implementation of a revised risk adjustment methodology for 2027 that further separates MA-PDs and PDPs, reshaping plan incentives and potentially impacting drug spending and population health strategies (Avalere Health Advisory, HFMA summary). Meanwhile, CMS’s BALANCE program, aimed at expanding access to GLP-1 therapies for obesity and related comorbidities via value-based contracts, has seen delays in its Part D component, reflecting ongoing operational and budgetary tensions as payers and providers grapple with the integration of high-cost drugs into accountable care models (KFF analysis).
Related Articles
EPA to put microplastics on study list of contaminants in drinking water
The EPA names microplastics as a potential drinking water contaminant, a move that is seen as an appeal to Kennedy's MAHA movement.
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S.
Under the Magnifying Glass: A Wave of Drug Price Transparency
Public Opinion on Prescription Drugs and Their Prices
This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences ...
Bipartisan bill would cap insulin at $35 per month
Bipartisan bill would cap insulin at $35 per month Becker's Hospital Review
Understanding The Explanations For The 2027 Medicare Drug Price Negotiation Cycle
Understanding The Explanations For The 2027 Medicare Drug Price Negotiation Cycle Health Affairs
IRA Drug Provisions Linked to Significant Drop in Medicare Medication Nonadherence
CVS reaches insulin pricing settlement with FTC
CVS reaches insulin pricing settlement with FTC Health Leaders Media
CVS Caremark, FTC reach settlement in insulin pricing case
CVS Caremark, FTC reach settlement in insulin pricing case Fierce Healthcare
STAT+: FTC strikes proposed deal with CVS over charges its PBM manipulated insulin prices, impeded access
The FTC said the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.